{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:13:25Z","timestamp":1791414805222,"version":"4.3.3"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1097\/md.0000000000002473","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T07:42:41Z","timestamp":1455262961000},"page":"e2473","source":"Crossref","is-referenced-by-count":26,"title":["Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder"],"prefix":"10.1097","volume":"95","author":[{"given":"Santiago","family":"S\u00e1nchez-Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Garc\u00eda-Solaesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Garc\u00eda-Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Sanchez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lorenzo-Romo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Mart\u00edn-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gaedigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Gonz\u00e1lez-Buitrago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Isidoro-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210509","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cll.2008.05.003","article-title":"Pharmacogenetic testing in psychiatry: a review of features and clinical realities","volume":"28","author":"de Leon","year":"2008","journal-title":"Clin Lab Med"},{"key":"R2-13-20210509","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S1092852900020022","article-title":"DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping","volume":"14","author":"de Leon","year":"2009","journal-title":"CNS Spectr"},{"key":"R3-13-20210509","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Thera"},{"key":"R4-13-20210509","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40265-015-0375-0","article-title":"Clinical association between pharmacogenomics and adverse drug reactions","volume":"75","author":"Zhou","year":"2015","journal-title":"Drugs"},{"key":"R5-13-20210509","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R6-13-20210509","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R7-13-20210509","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R8-13-20210509","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/pr.58.3.6","article-title":"Pharmacogenetics, drug-metabolizing enzymes, and clinical practice","volume":"58","author":"Gardiner","year":"2006","journal-title":"Pharm Rev"},{"key":"R9-13-20210509","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1373\/clinchem.2004.041327","article-title":"Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy","volume":"51","author":"Steimer","year":"2005","journal-title":"Clin Chem"},{"key":"R10-13-20210509","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000223734","article-title":"CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study","volume":"59","author":"Kobylecki","year":"2009","journal-title":"Neuropsychobiology"},{"key":"R11-13-20210509","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","article-title":"CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine","volume":"31","author":"Shams","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"R12-13-20210509","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fphar.2011.00006","article-title":"Pharmacogenetics of antidepressants","volume":"2","author":"Crisafulli","year":"2011","journal-title":"Front Pharm"},{"key":"R13-13-20210509","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1176\/appi.psy.44.6.515","article-title":"Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II","volume":"44","author":"Armstrong","year":"2003","journal-title":"Psychosomatics"},{"key":"R14-13-20210509","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1389200215666140202215316","article-title":"Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization","volume":"15","author":"Hicks","year":"2014","journal-title":"Curr Drug Metab"},{"key":"R15-13-20210509","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03256453","article-title":"The AmpliChip CYP450 genotyping test: integrating a new clinical tool","volume":"10","author":"de Leon","year":"2006","journal-title":"Mol Diagn Ther"},{"key":"R17-13-20210509","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s004310100767","article-title":"Mu[Combining Diaeresis]ller CR, European Molecular Genetics Quality Network. Quality control in mutation analysis: The EMQN.","volume":"160","year":"2001","journal-title":"Eur J Pediatr"},{"key":"R18-13-20210509","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.cr.7290272","article-title":"SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci","volume":"15","author":"Shi","year":"2005","journal-title":"Cell Res"},{"key":"R19-13-20210509","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/pgs.11.107","article-title":"Detection and characterization of the CYP2D6 * 9x2 gene duplication in two Spanish populations: resolution of AmpliChip CYP450 test no-calls","volume":"12","author":"Gaedigk","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R20-13-20210509","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00228-010-0831-4","article-title":"Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations","volume":"66","author":"Gaedigk","year":"2010","journal-title":"Eur J Clin Pharm"},{"key":"R21-13-20210509","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14622416.5.7.895","article-title":"Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population","volume":"5","author":"Solus","year":"2004","journal-title":"Pharmacogenomics"},{"key":"R22-13-20210509","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"R23-13-20210509","first-page":"103","article-title":"Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects","volume":"22","author":"Zourkova","year":"2003","journal-title":"Gen Physiol Biophys"},{"key":"R24-13-20210509","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jcpt.12042","article-title":"Dynamics and persistence of CYP2D6 inhibition by paroxetine","volume":"38","author":"Jurica","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"R25-13-20210509","doi-asserted-by":"crossref","first-page":"D237","DOI":"10.1093\/nar\/gkp970","article-title":"SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions","volume":"38","author":"Preissner","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"R26-13-20210509","first-page":"17","article-title":"The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications","volume":"27","author":"van der Weide","year":"2006","journal-title":"Clin Biochem Rev"},{"key":"R27-13-20210509","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"key":"R28-13-20210509","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.4088\/JCP.09r05259gre","article-title":"The neurobiology of the switch process in bipolar disorder: a review","volume":"71","author":"Salvadore","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R29-13-20210509","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00002018-200326050-00003","article-title":"Avoiding drug-induced switching in patients with bipolar depression","volume":"26","author":"Henry","year":"2003","journal-title":"Drug Safety"},{"key":"R30-13-20210509","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1590\/S1516-44462003000300010","article-title":"Manic episodes during antidepressant treatment in bipolar disorder","volume":"25","author":"Tamada","year":"2003","journal-title":"Rev Bras Psiquiatr"},{"key":"R31-13-20210509","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.4088\/JCP.v68n1002","article-title":"Self-reported history of manic\/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"68","author":"Truman","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R32-13-20210509","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1176\/appi.ajp.2007.05122032","article-title":"Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD","volume":"164","author":"Goldberg","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R33-13-20210509","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4088\/JCP.08m04995gre","article-title":"A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)","volume":"71","author":"Young","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R34-13-20210509","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/JCP.0b013e3181f15849","article-title":"Treatment options for bipolar depression: a systematic review of randomized, controlled trials","volume":"30","author":"Vieta","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R35-13-20210509","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00702-014-1340-x","article-title":"Personalized therapies in psychiatry: promises, pitfalls and perspectives","volume":"122","author":"Domschke","year":"2015","journal-title":"J Neural Transm"},{"key":"R36-13-20210509","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/phar.1398","article-title":"Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options","volume":"34","author":"Drozda","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R37-13-20210509","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","article-title":"Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19","volume":"47","author":"de Leon","year":"2006","journal-title":"Psychosomatics"},{"key":"R38-13-20210509","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R40-13-20210509","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal Bioanal Chem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000002473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:34:57Z","timestamp":1786041297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201602090-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002473","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}